<ѻýҕl>VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapyѻýҕl> Prospective study in heavily treated population is warranted, researcher says Mar 30, 2023
<ѻýҕl>Novel Strategies Show Winning Potential in Ovarian Cancerѻýҕl> High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib Mar 28, 2023
<ѻýҕl>CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancerѻýҕl> Responses in a fourth of patients, clinical benefit in up to 90% Mar 26, 2023
<ѻýҕl>OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancerѻýҕl> Significant PFS results demonstrated in NORA trial don't extend to overall survival Dec 17, 2022
<ѻýҕl>FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancerѻýҕl> Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial Nov 15, 2022
<ѻýҕl>Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomesѻýҕl> One in five patients experienced changes in their care plan Oct 04, 2022
<ѻýҕl>Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancerѻýҕl> PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says Oct 01, 2022
<ѻýҕl>'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancerѻýҕl> Post-hoc data from SOLO3 show diverging results based on prior lines of therapy Sep 30, 2022
<ѻýҕl>Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trialsѻýҕl> Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
<ѻýҕl>Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancerѻýҕl> A closer look at why PARP inhibitor's third-line indication was withdrawn Sep 09, 2022
<ѻýҕl>Does PARP Inhibitor Maintenance Induce Platinum Resistance in Ovarian Cancer?ѻýҕl> Shorter progression-free interval with platinum chemotherapy after olaparib maintenance Sep 01, 2022
<ѻýҕl>Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancerѻýҕl> Lower all-cause, cancer-specific mortality in women who received the drugs around time of surgery Aug 29, 2022
<ѻýҕl>Two Sides of Endosalpingiosis: Benign Growth or Harbinger of Cancer?ѻýҕl> Concurrent malignancy more than twice as common as compared with endometriosis, study showed Aug 06, 2022
<ѻýҕl>Prosthetic Mesh May Stand in the Way of Further Abdominal Operationsѻýҕl> Prior incisional hernia repair associated with complications with later abdominal surgery Aug 04, 2022
<ѻýҕl>Another Possible Use for Aspirin: Reducing Ovarian Cancer Riskѻýҕl> Potential benefit seen in women with and without established cancer risk factors Jul 27, 2022
<ѻýҕl>Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancerѻýҕl> Decision on rucaparib follows negative OS signal and "discussions" with FDA Jun 17, 2022
<ѻýҕl>PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancerѻýҕl> Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy Jun 07, 2022
<ѻýҕl>New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomyѻýҕl> Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
<ѻýҕl>Artificial Sweeteners Not So Sweet When It Comes to Cancer Riskѻýҕl> Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
<ѻýҕl>Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancerѻýҕl> Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
<ѻýҕl>Novel ADC Promising in Tough-to-Treat Ovarian Cancerѻýҕl> Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease Mar 20, 2022
<ѻýҕl>Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancerѻýҕl> Study suggests no improvement in overall survival Mar 19, 2022
<ѻýҕl>Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancerѻýҕl> Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
<ѻýҕl>A Better Option for Preserving Fertility in Gynecologic Cancer Patients?ѻýҕl> In vitro maturation can result in both embryos and oocyte vitrification, researcher says Oct 19, 2021
<ѻýҕl>Christiane Amanpour's Ovarian Cancer and the Importance of Early Detectionѻýҕl> Renowned reporter calls on women to advocate for themselves Oct 11, 2021
<ѻýҕl>Another Checkpoint Inhibitor Misses Mark in Ovarian Cancerѻýҕl> No OS or PFS benefit with nivolumab versus chemotherapy for platinum-resistant disease Sep 24, 2021
<ѻýҕl>Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancerѻýҕl> Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
<ѻýҕl>Third Dose a Charm in Israel? Door-to-Door 'Goons'; Cervids Catch COVID, Too!ѻýҕl> A daily roundup of news on COVID-19 and the rest of medicine Jul 30, 2021
<ѻýҕl>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care?ѻýҕl> News, features, and commentary about cancer-related issues Jun 10, 2021
<ѻýҕl>Ovarian Cancer Screening Trial Still Sees No Death Reductionѻýҕl> Researchers "disappointed" by long-term results of U.K. study of 200,000 postmenopausal women May 22, 2021
<ѻýҕl>Report: Worst Hospitals for Unnecessary Proceduresѻýҕl> Lown Institute says report is the first to name hospitals with high rates of overuse May 04, 2021
<ѻýҕl>Triage System Gets High Marks for Ovarian Cancer Debulking Surgeryѻýҕl> Key factors predicted threefold higher risk of 90-day mortality with primary surgery Mar 26, 2021
<ѻýҕl>HIPEC Combo Doubles PFS in Advanced Ovarian Cancerѻýҕl> Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study Mar 26, 2021
<ѻýҕl>Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancerѻýҕl> Ixabepilone plus bevacizumab yielded responses in a third of patients Mar 26, 2021
<ѻýҕl>Androgen Receptor Inhibitor Active in Endometrial Cancerѻýҕl> SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
<ѻýҕl>Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancerѻýҕl> Responses in 37% of patients with AVB-500, higher without prior bevacizumab Mar 21, 2021
<ѻýҕl>Is MIS Viable for Interval Debulking in Ovarian Cancer?ѻýҕl> Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy Mar 21, 2021
<ѻýҕl>PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancerѻýҕl> Modest improvement in PFS with rucaparib but worse outcome for reversion mutation Mar 20, 2021
<ѻýҕl>New Targeted Therapies Show Promise in Cancerѻýҕl> Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
<ѻýҕl>Kardashian Makeup Artist Hrush Achemyan's Ovarian Cancerѻýҕl> Beauty influencer reveals diagnosis Jan 21, 2021